Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist.
Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.
He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he worked with research groups focusing on autoimmunity.
He said: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes.
“I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that makes a difference for patients.”
Alan Moses, CMO of Novo Nordisk, added: “With [Gough’s] key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk’s ambition of changing diabetes.”